LY450108

CAS No. 376594-67-1

LY450108( —— )

Catalog No. M29625 CAS No. 376594-67-1

LY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 39 In Stock
5MG 35 In Stock
10MG 57 In Stock
25MG 98 In Stock
50MG 145 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    LY450108
  • Note
    Research use only, not for human use.
  • Brief Description
    LY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.
  • Description
    LY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.
  • In Vitro
    AMPA receptors mediate most of the excitatory neurotransmission and play a key role in synaptic plasticity in the mammalian central nervous system (CNS). Recent evidence has shown that in addition to modulating fast synaptic plasticity and memory processes, AMPA receptor potentiators alter downstream signalling pathways and may thereby have utility in other CNS disorders.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    iGluR
  • Recptor
    iGluR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    376594-67-1
  • Formula Weight
    396.45
  • Molecular Formula
    C19H22F2N2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 50 mg/mL (126.12 mM)
  • SMILES
    CC(C)S(NC[C@H](C)c(cc1)ccc1NC(c1cc(F)cc(F)c1)=O)(=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • CGP 78608 hydrochlor...

    CGP 78608 hydrochloride is a specific antagonist at the glycine binding site of the NMDA receptor (IC50 = 6 nM). CGP 78608 hydrochloride exhibits anticonvulsant activity.

  • Rislenemdaz

    A potent, orally bioavailable brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively.

  • TAK-137

    TAK-137 is an AMPA receptor enhancer with antidepressant effects. TAK-137 has the ability to improve cognition and could be used to study schizophrenia.